Back to Search
Start Over
CD34 + cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina.
- Source :
-
Stem cells translational medicine [Stem Cells Transl Med] 2020 Oct; Vol. 9 (10), pp. 1147-1152. Date of Electronic Publication: 2020 Jun 12. - Publication Year :
- 2020
-
Abstract
- Patients with refractory angina who are suboptimal candidates for further revascularization have improved exercise time, decreased angina frequency, and reduced major adverse cardiac events with intramyocardial delivery of CD34 <superscript>+</superscript> cells. However, the effect of CD34 <superscript>+</superscript> cell therapy on health care expenditures before and after treatment is unknown. We determined the effect of CD34 <superscript>+</superscript> cell therapy on cardiac-related hospital visits and costs during the 12 months following stem cell injection compared with the 12 months prior to injection. Cardiac-related hospital admissions and procedures were retrospectively tabulated for patients enrolled at one site in one of three double-blinded, placebo-controlled CD34 <superscript>+</superscript> trials in the 12 months before and after intramyocardial injections of CD34 <superscript>+</superscript> cells vs placebo. Fifty-six patients were randomized to CD34 <superscript>+</superscript> cell therapy (n = 37) vs placebo (n = 19). Patients randomized to cell therapy experienced 1.57 ± 1.39 cardiac-related hospital visits 12 months before injection, compared with 0.78 ± 1.90 hospital visits 12 months after injection, which was associated with a 62% cost reduction translating to an average savings of $5500 per cell therapy patient. Patients in the placebo group also demonstrated a reduction in cardiac-related hospital events and costs, although to a lesser degree than the CD34 <superscript>+</superscript> group. Through 1 January 2019, 24% of CD34 <superscript>+</superscript> subjects died at an average of 6.5 ± 2.4 years after enrollment, whereas 47% of placebo patients died at an average of 3.7 ± 1.9 years after enrollment. In conclusion, CD34 <superscript>+</superscript> cell therapy for subjects with refractory angina is associated with improved mortality and a reduction in hospital visits and expenditures for cardiac procedures in the year following treatment.<br /> (© 2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.)
Details
- Language :
- English
- ISSN :
- 2157-6580
- Volume :
- 9
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Stem cells translational medicine
- Publication Type :
- Academic Journal
- Accession number :
- 32531108
- Full Text :
- https://doi.org/10.1002/sctm.20-0046